Mineralys Therapeutics, INC. (MLYS) — SEC Filings

Latest SEC filings for Mineralys Therapeutics, INC.. Recent 4 filing on Apr 21, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Mineralys Therapeutics, INC. on SEC EDGAR

Overview

Mineralys Therapeutics, INC. (MLYS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 21, 2026: On April 17, 2026, David Malcom Rodman reported a change in beneficial ownership of securities for Mineralys Therapeutics, Inc. The filing details transactions related to his holdings, but specific dollar amounts and the exact nature of the transactions are not provided in this summary.

Sentiment Summary

Across 42 filings, the sentiment breakdown is: 39 neutral, 3 mixed. The dominant filing sentiment for Mineralys Therapeutics, INC. is neutral.

Filing Type Overview

Mineralys Therapeutics, INC. (MLYS) has filed 6 4, 1 DEFA14A, 6 10-Q, 18 8-K, 2 DEF 14A, 2 10-K, 2 SC 13G/A, 4 SC 13G, 1 SC 13D/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (42)

Mineralys Therapeutics: Ownership Change Reported — 4 · Apr 21, 2026 Risk: low
On April 17, 2026, David Malcom Rodman reported a change in beneficial ownership of securities for Mineralys Therapeutics, Inc. The filing details transactions
Mineralys Therapeutics Files Form 4 — 4 · Apr 16, 2026 Risk: low
On April 15, 2026, Mineralys Therapeutics, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The filing pertains to the period of re
Mineralys Therapeutics Files Form 4 — 4 · Apr 16, 2026 Risk: low
On April 15, 2026, Mineralys Therapeutics, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The report covers transactions that occ
Mineralys Therapeutics Files Form 4 — 4 · Apr 14, 2026 Risk: low
On April 13, 2026, Mineralys Therapeutics, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The report covers transactions that occ
DEFA14A Filing — DEFA14A · Apr 8, 2026
4 Filing — 4 · Apr 2, 2026
4 Filing — 4 · Apr 2, 2026
Mineralys Narrows Losses, Boosts Cash with $459M in Offerings — 10-Q · Nov 10, 2025 Risk: medium
Mineralys Therapeutics, Inc. (MLYS) reported a net loss of $36.9 million for the three months ended September 30, 2025, a significant improvement from the $56.3
Mineralys Therapeutics Files 8-K — 8-K · Sep 3, 2025 Risk: low
Mineralys Therapeutics, Inc. filed an 8-K on September 3, 2025, reporting other events and financial statements. The filing details the company's incorporation
Mineralys Therapeutics Files 8-K — 8-K · Sep 2, 2025 Risk: medium
Mineralys Therapeutics, Inc. filed an 8-K on September 2, 2025, to report "Other Events." The filing does not contain specific details about the nature of these
Mineralys' Losses Mount Amid R&D Spend, Cash Position Strong — 10-Q · Aug 12, 2025 Risk: high
Mineralys Therapeutics, Inc. reported a net loss of $43.3 million for the three months ended June 30, 2025, an increase from $41.0 million in the prior-year per
Mineralys Therapeutics Files 8-K — 8-K · Jun 17, 2025 Risk: low
Mineralys Therapeutics, Inc. filed an 8-K on June 17, 2025, reporting on several items including Regulation FD Disclosure, Other Events, and Financial Statement
Mineralys Therapeutics Files 8-K — 8-K · May 22, 2025 Risk: low
Mineralys Therapeutics, Inc. filed an 8-K on May 22, 2025, reporting the submission of matters to a vote of security holders and financial statements and exhibi
Mineralys Therapeutics Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: low
Mineralys Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, incorporated in Delaware, operates in the Pharmaceutical Preparat
Mineralys Therapeutics 2025 Annual Meeting Proxy Statement — DEF 14A · Apr 9, 2025 Risk: low
Mineralys Therapeutics, Inc. is holding its 2025 Annual Meeting of Stockholders on May 22, 2025. The proxy statement details the proposals to be voted on, inclu
Mineralys Therapeutics Files 8-K — 8-K · Mar 31, 2025 Risk: low
Mineralys Therapeutics, Inc. filed an 8-K on March 31, 2025, reporting events that occurred on March 29, 2025. The filing includes information related to Regula
Mineralys Therapeutics Files 8-K — 8-K · Mar 12, 2025 Risk: low
Mineralys Therapeutics, Inc. filed an 8-K on March 12, 2025, reporting on events that occurred on March 11, 2025. The filing primarily concerns "Other Events" a
Mineralys Therapeutics Files 8-K — 8-K · Mar 10, 2025 Risk: low
Mineralys Therapeutics, Inc. filed an 8-K on March 10, 2025, to report on various events. The filing includes information related to Regulation FD Disclosure, O
10-K Filing — 10-K · Feb 12, 2025
Mineralys Therapeutics Files 8-K — 8-K · Feb 4, 2025 Risk: low
Mineralys Therapeutics, Inc. filed an 8-K on February 4, 2025, to report on other events and financial statements. The filing does not contain specific financia
Mineralys Therapeutics Files 8-K — 8-K · Jan 8, 2025 Risk: low
Mineralys Therapeutics, Inc. filed an 8-K on January 8, 2025, to report on other events and financial statements. The filing does not contain specific financial
SC 13G/A Filing — SC 13G/A · Nov 13, 2024
SC 13G/A Filing — SC 13G/A · Nov 13, 2024
Mineralys Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
Mineralys Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, incorporated in Delaware, operates in the Pharmaceutical Prep
Mineralys Therapeutics Files 8-K — 8-K · Oct 30, 2024 Risk: low
Mineralys Therapeutics, Inc. filed an 8-K on October 30, 2024, to report on other events and financial statements. The filing does not contain specific details
Mineralys Therapeutics Files 8-K — 8-K · Sep 25, 2024 Risk: low
Mineralys Therapeutics, Inc. filed an 8-K on September 25, 2024, to report on other events and financial statements. The filing does not contain specific financ
Mineralys Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
Mineralys Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business
Mineralys Therapeutics Appoints New Directors, Updates Executive Contracts — 8-K · Jun 14, 2024 Risk: low
Mineralys Therapeutics, Inc. announced on June 13, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company el
Mineralys Therapeutics Files 8-K — 8-K · Jun 10, 2024 Risk: low
Mineralys Therapeutics, Inc. filed an 8-K on June 10, 2024, reporting other events and financial statements. The company, incorporated in Delaware with its prin
Mineralys Therapeutics Files 8-K — 8-K · May 31, 2024 Risk: low
Mineralys Therapeutics, Inc. filed an 8-K on May 31, 2024, to report financial statements and exhibits. The filing does not contain specific financial figures o
Mineralys Therapeutics Reports on Shareholder Votes — 8-K · May 22, 2024 Risk: low
Mineralys Therapeutics, Inc. filed an 8-K on May 22, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specifi
Mineralys Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
Mineralys Therapeutics, Inc. (MLYS) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Mineralys Therapeutics, Inc. filed a 10-Q report for the quarte
Mineralys Therapeutics, Inc. Announces Annual Meeting of Stockholders — DEF 14A · Apr 9, 2024 Risk: low
Mineralys Therapeutics, Inc. (MLYS) filed a Proxy Statement (DEF 14A) with the SEC on April 9, 2024. Annual meeting scheduled for May 22, 2024, at 12:00 p.m. Ea
Mineralys Therapeutics Announces Board and Executive Changes — 8-K · Apr 4, 2024 Risk: medium
Mineralys Therapeutics, Inc. announced on March 29, 2024, changes in its board of directors and executive compensation arrangements. The filing details the depa
Mineralys Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 21, 2024 Risk: low
Mineralys Therapeutics, Inc. (MLYS) filed a Annual Report (10-K) with the SEC on March 21, 2024. Mineralys Therapeutics, Inc. filed its 2023 Form 10-K on March
SC 13G Filing — SC 13G · Feb 15, 2024
SC 13G Filing — SC 13G · Feb 14, 2024
SC 13G Filing — SC 13G · Feb 13, 2024
SC 13G Filing — SC 13G · Feb 13, 2024
Samsara BioCapital Amends Mineralys Therapeutics Stake — SC 13D/A · Feb 12, 2024 Risk: medium
Samsara BioCapital, L.P. filed an amended Schedule 13D on February 12, 2024, regarding its ownership in Mineralys Therapeutics, Inc. This amendment, filed by Sa
MLYS Reports Material Agreement, Unregistered Equity Sales — 8-K · Feb 8, 2024 Risk: medium
Mineralys Therapeutics, Inc. (MLYS) filed an 8-K on February 8, 2024, reporting an "Entry into a Material Definitive Agreement" and "Unregistered Sales of Equit
Mineralys Therapeutics Files Routine 8-K, Confirms Nasdaq Listing — 8-K · Jan 4, 2024
Mineralys Therapeutics, Inc. filed an 8-K on January 4, 2024, to report general corporate information and confirm its status as a publicly traded company on The

Frequently Asked Questions

What are the latest SEC filings for Mineralys Therapeutics, INC. (MLYS)?

Mineralys Therapeutics, INC. has 42 recent SEC filings from Jan 2024 to Apr 2026, including 18 8-K, 6 4, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of MLYS filings?

Across 42 filings, the sentiment breakdown is: 39 neutral, 3 mixed. The dominant sentiment is neutral.

Where can I find Mineralys Therapeutics, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Mineralys Therapeutics, INC. (MLYS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.